A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder

ResearchSpace/Manakin Repository

Full text options

Find Full text

This item appears in the following Collection(s)

https://creativecommons.org/licenses/by/4.0/ Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/

Share

Search ResearchSpace


Advanced Search

Browse